Ed­uar­do Bra­vo re­turns to bring Eu­ro­pean biotech in on the SPAC splurge

The last year’s SPAC boom has been dom­i­nat­ed so far by US-based VCs. Now a promi­nent Eu­ro­pean biotech ex­ec­u­tive and a cou­ple in­vestors are get­ting in on the game.

Ed­uar­do Bra­vo, the Big Phar­ma alum and for­mer CEO of the cell ther­a­py com­pa­ny TiGenix, has launched Eu­ro­pean Biotech Ac­qui­si­tion. Based in Am­s­ter­dam (if a SPAC can be said to be based any­where be­sides the Cay­man Is­lands and Ama­zon Web Ser­vices), the new shell com­pa­ny will try to raise $100 mil­lion and use it to take a Eu­ro­pean biotech pub­lic with­in 2 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER